Discussion ICC accounts for 10–15% of all cases of primary liver cancer, with an increasing trend in incidence in recent years 27 .
← all excerpts
Anlotinib suppresses tumor progression via blocking the VEGFR2/PI3K/AKT cascade in intrahepatic cholangiocarcinoma.
1
—
—